NCT01597349View on ClinicalTrials.gov

Antitussive Effects of FP01 Lozenges in Subjects With Cough Due to Upper Respiratory Tract Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

208

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

September 30, 2012

Study Completion Date

September 30, 2012

Conditions
Acute Cough
Interventions
DRUG

FP01

Lozenge 3 times per day, low dose, high dose, or placebo for 48 hours.

Trial Locations (5)

7510524

Clinica Las Lilas, Santiago

Unknown

Biomedical Research Group, Santiago

Clinica Internacional Sede Lima, Lima

Clinica Internacional Sede San Borja, Lima

Unidad de Investigación Clinica San Pablo, Lima

Sponsors
All Listed Sponsors
lead

Avalo Therapeutics, Inc.

INDUSTRY

NCT01597349 - Antitussive Effects of FP01 Lozenges in Subjects With Cough Due to Upper Respiratory Tract Infection | Biotech Hunter | Biotech Hunter